Drug General Information
Drug ID	D0D4IG
Former ID	DNC012460
Drug Name	5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[551311]
Structure		Download 2D MOL 3D MOL
Formula	C8H3Cl3N2O2
Canonical SMILES	C1=C2C(=C(C(=C1Cl)Cl)Cl)NC(=O)C(=O)N2
InChI	1S/C8H3Cl3N2O2/c9-2-1-3-6(5(11)4(2)10)13-8(15)7(14)12-3/h1H,(H,12,14)(H,13,15)
InChIKey	MVCXAPXDPCEJBN-UHFFFAOYSA-N
PubChem Compound ID	10849325
Target and Pathway
Target(s)	NMDA receptor subunit NR1	Target Info	Inhibitor	[551311]
KEGG Pathway	Ras signaling pathway
	Rap1 signaling pathway
	Calcium signaling pathway
	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Circadian entrainment
	Long-term potentiation
	Glutamatergic synapse
	Alzheimer's disease
	Amyotrophic lateral sclerosis (ALS)
	Huntington's disease
	Cocaine addiction
	Amphetamine addiction
	Nicotine addiction
	Alcoholism
PANTHER Pathway	Huntington disease
	Ionotropic glutamate receptor pathway
	Metabotropic glutamate receptor group III pathway
	Metabotropic glutamate receptor group I pathway
	Muscarinic acetylcholine receptor 1 and 3 signaling pathway
Reactome	EPHB-mediated forward signaling
	Unblocking of NMDA receptor, glutamate binding and activation
	CREB phosphorylation through the activation of CaMKII
	Ras activation uopn Ca2+ infux through NMDA receptor
	RAF/MAP kinase cascade
WikiPathways	SIDS Susceptibility Pathways
	Hypothetical Network for Drug Addiction
	Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
	Spinal Cord Injury
	BDNF signaling pathway
	Alzheimers Disease
References
Ref 551311	1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996).
Ref 551311	1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.